PARSIPPANY, NJ--(Marketwire - May 16, 2008) - Daiichi Sankyo, Inc. (DSI) announced today that data from two pooled analyses further demonstrate that Welchol™ (colesevelam HCl), in combination with metformin -- or sulfonylurea-based therapy, significantly lowers blood glucose (as measured by A1C) in patients with type 2 diabetes mellitus who had failed to achieve glycemic control (ADA target of A1C < 7%). These findings, presented at the American Association of Clinical Endocrinologists’ (AACE) 17th Annual Meeting and Clinical Congress, are the latest in a series of diabetes-related milestones for Welchol. In April, DSI announced that Welchol was added to the American College of Endocrinology (ACE)/AACE “Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus.”
